Astrazeneca AB has synthesized fibroblast activation protein-α (FAPα) inhibitors reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH), among others.
Astrazeneca AB has disclosed 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic steatosis, liver inflammation, hepatitis C virus infection and liver cancer.
Astrazeneca AB has disclosed bicyclic heteroaromatic compounds acting as transcriptional enhancer factor (TEAD) and TEAD-4 inhibitors reported to be useful for the treatment of cancer.
Astrazeneca AB has synthesized IL-1 receptor-associated kinase 4 (IRAK4) inhibitors reported to be useful for the treatment of cancer, systemic lupus erythematosus, gout, rheumatoid arthritis, psoriasis, Sjögren’s syndrome, myositis and atopic dermatitis, among others.
Astrazeneca AB has synthesized pyraolo-and triazolo-azinone compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of neurological disorders.
Astrazeneca AB has synthesized octahydrofuro[3,4-b]pyrazines acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, cardiovascular and metabolic disorders.
A recent Astrazeneca AB patent describes 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of type 2 diabetes.
Astrazeneca has described spirocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. have divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.
